Huguet, J.M.; GarcÃa-Lorenzo, V.; MartÃ, L.; Paredes, J.M.; RamÃrez, J.J.; Pastor, M.; Ruiz, L.; Sanahuja, A.; Timoneda, P.; SanchÃs, L.;
et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines 2022, 10, 2130.
https://doi.org/10.3390/biomedicines10092130
AMA Style
Huguet JM, GarcÃa-Lorenzo V, Martà L, Paredes JM, RamÃrez JJ, Pastor M, Ruiz L, Sanahuja A, Timoneda P, SanchÃs L,
et al. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines. 2022; 10(9):2130.
https://doi.org/10.3390/biomedicines10092130
Chicago/Turabian Style
Huguet, Jose M., Victor GarcÃa-Lorenzo, Lidia MartÃ, Jose MarÃa Paredes, Jose Joaquin RamÃrez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura SanchÃs,
and et al. 2022. "Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study" Biomedicines 10, no. 9: 2130.
https://doi.org/10.3390/biomedicines10092130
APA Style
Huguet, J. M., GarcÃa-Lorenzo, V., MartÃ, L., Paredes, J. M., RamÃrez, J. J., Pastor, M., Ruiz, L., Sanahuja, A., Timoneda, P., SanchÃs, L., Pérez, G. A., & Boscá-Watts, M. M.
(2022). Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study. Biomedicines, 10(9), 2130.
https://doi.org/10.3390/biomedicines10092130
